Observing cancer outcomes in patients receiving integrative oncology care

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to evaluate disease-free survival in early-stage cancer patients and overall survival outcomes in advanced-stage cancer patients receiving Advanced Integrative Oncology (AIO) treatment. It will collect data from patients at the AIMS Institute, focusing on the effectiveness of naturopathic medicine integrated with conventional cancer treatments. The study addresses a gap in knowledge regarding the outcomes of patients utilizing complementary and alternative medicine therapies in conjunction with standard oncology care.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. A new patient coming in for a first office call (FOC) or first consultation via telemedicine with a diagnosis of cancer, or
2. An established patient with a diagnosis of cancer receiving treatment at the AIMS Institute;
3. If over 18 years of age are able to understand study design adequately and provide signed informed consent (IC) to enrollment;
4. If younger than 18 years of age informed assent from the child and informed consent from a parent or guardian who is able to understand the study design adequately and provide signed informed consent for the pediatric patient;
5. A confirmed diagnosis of cancer based on medical oncology medical records.

Exclusion Criteria:

1. Patients not diagnosed with cancer;
2. Telehealth patients;
3. Cannot read or understand English well enough to read and sign the consent form and complete the questionnaires;
4. Unwilling to participate in the AIMS Institute observational study.

Where it's running

• AIMS Institute
  Seattle, Washington, United States Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Treatment of metastatic solid tumors with SLV-154

  This study is testing a new treatment called SLV-154 for people with advanced solid tumors, like certain types of lung and breast cancer, to see how safe it is and how well it works.

  Recruiting at 12 sites Phase 1 Solve Therapeutics · Newport Beach, California and 11 other locations · NCT06771219

• Evaluating ALK202 for advanced solid tumors

  This study is testing a new drug called ALK202 to see if it is safe and effective for adults with advanced solid tumors.

  Recruiting at 4 sites Phase 1 Shanghai Allink Biotherapeutics Co., Ltd. · Margate, Florida and 3 other locations · NCT06707610

• Oral Alintegimod with Ipilimumab followed by Nivolumab for advanced cancer

  This study is testing if a new oral medication called Alintegimod, combined with two other cancer treatments, can help people with advanced solid tumors feel better and live longer.

  Recruiting at 4 sites Phase 1/2 7 Hills Pharma, LLC · Aurora, Colorado and 4 other locations · NCT06362369

• Testing MGC026 in patients with advanced solid tumors

  This study is testing a new treatment called MGC026 to see if it can help adults with advanced solid tumors that can't be removed or have spread to other parts of the body.

  Recruiting at 12 sites Phase 1 MacroGenics · Los Angeles, California and 11 other locations · NCT06242470

• Evaluating CJRB-101 with Pembrolizumab for Advanced Cancer

  This study is testing a new treatment combining CJRB-101 with pembrolizumab to see if it helps people with advanced cancers like lung cancer and melanoma feel better and respond better to their treatment.

  Recruiting at 4 sites Phase 1/2 CJ Bioscience, Inc. · Irvine, California and 3 other locations · NCT05877430

• Testing BIO-106 with pembrolizumab in patients with advanced cancers

  This study is testing a new treatment called BIO-106, both alone and with pembrolizumab, to see if it can help people with advanced cancers that haven't responded to other therapies.

  Recruiting at 3 sites Phase 1/2 BiOneCure Therapeutics Inc. · Austin, Texas and 2 other locations · NCT05320588

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.